> ## Content Index > Fetch the complete content index at: https://www.sanarelab.science/llms.txt > Use this file to discover other available public pages before exploring further. # Curcumin Curbs Colorectal Polyp Regrowth in 577-Patient RCT - URL: https://www.sanarelab.science/curcumin-curbs-colorectal-polyp-regrowth-577-patient-rct-2026/ - Published: 2026-09-05T08:15:45.000Z - Updated: 2026-09-05T08:15:45.000Z - Description: A 577-patient randomized trial shows curcumin significantly suppresses growth of recurrent colorectal adenomas ≥6 mm after endoscopic polypectomy, with minimal side effects over 2 years. - Author: Sanare Lab - Tags: #short-read, News, Research, curcumin Key Takeaway A 577-patient randomized, double-blind, placebo-controlled trial (J-CAP-C) found that oral submicron-powdered curcumin (Theracurmin® 180 mg twice daily) significantly reduced the growth of recurrent colorectal adenomas ≥6 mm after endoscopic polypectomy. The risk ratio was 0.56 (95% CI 0.33–0.95; P=0.04), and the median size of all detected adenomas was also significantly smaller. No meaningful safety concerns were observed over two years. This is the first large-scale RCT demonstrating a chemopreventive effect of curcumin against colorectal neoplasia regrowth. Colorectal adenomas are the most common precancerous lesions of the colon and rectum. After endoscopic polypectomy, they frequently recur, and a subset grows large enough to require repeat intervention. Dietary and supplemental interventions that can slow this regrowth—or limit the size of recurring polyps—are of substantial interest to patients and clinicians alike. Curcumin, the principal polyphenol in turmeric, has shown chemopreventive activity in preclinical models and small human studies. Its poor bioavailability has historically limited clinical translation, but newer formulations such as submicron-powdered curcumin (Theracurmin®) have improved absorption. The newly published J-CAP-C trial, led by Tokushima University and published in the *American Journal of Gastroenterology*, is the largest and most rigorous curcumin cancer-prevention study to date. It enrolled 577 patients across multiple Japanese centers and tracked recurrence for two full years. Patients exploring [curcumin and cancer research](https://www.sanarelab.science/curcumin-and-cancer-what-human-and-preclinical-research-actually-shows/) will find this trial particularly relevant because it moves beyond laboratory data into real-world clinical evidence. Anyone evaluating a personal protocol that includes curcumin may also benefit from the [dosing calculator](https://www.sanarelab.science/protocol-dosing-workspace/) to align supplement amounts with body weight and concurrent therapies. ## Table of Contents - [Study Design and Methods](#study-design-and-methods) - [Key Findings](#key-findings) - [What Makes This Trial Different](#what-makes-this-trial-different) - [Clinical Implications](#clinical-implications) - [Frequently Asked Questions](#faq) ## Study Design and Methods The J-CAP-C trial was a randomized, double-blind, placebo-controlled, multicenter study conducted in Japan. Enrollment ran from April 2016 through March 2020\. Patients who had previously undergone endoscopic resection of colorectal neoplasia were eligible. Participants were randomized 1:1 to receive either: - **Curcumin group:** oral submicron-powdered curcumin (Theracurmin®) 180 mg twice daily (360 mg total per day) - **Placebo group:** identical placebo capsules Both groups continued treatment for 24 months. The primary endpoint was the detection rate of recurrent colorectal adenomas at the 2-year follow-up colonoscopy. A prespecified secondary analysis focused on adenomas ≥6 mm—the size threshold recommended for endoscopic resection in Japanese guidelines. | Parameter | Curcumin (n=287) | Placebo (n=290) | | ---------------------------------------- | ---------------------------------- | ------------------- | | Primary endpoint: any adenoma recurrence | RR 0.98 (95% CI 0.82–1.16) | Reference | | Adenomas ≥6 mm | RR 0.56 (95% CI 0.33–0.95; P=0.04) | Reference | | Median adenoma size | Significantly smaller (P=0.003) | Reference | | Adverse events | Infrequent and mild | Infrequent and mild | ## Key Findings The headline result was nuanced: curcumin did not significantly reduce the overall incidence of recurrent adenomas. However, it did meaningfully suppress the growth of lesions that did recur. The most clinically relevant findings were: - **Adenomas ≥6 mm:** The detection rate was significantly lower in the curcumin group (risk ratio 0.56; 95% CI 0.33–0.95; P=0.04). The per-patient number of adenomas ≥6 mm was also lower (P=0.03). - **Median size:** All detected adenomas were significantly smaller in the curcumin group (P=0.003). - **Subgroup signal:** In exploratory analyses, the growth-suppressive effect appeared more pronounced in men and in patients with a higher baseline adenoma burden. These results suggest that curcumin may act as a growth inhibitor rather than a pure incidence blocker. In chemoprevention, slowing the progression of small lesions is itself a valuable outcome because larger adenomas carry higher malignant potential. ## What Makes This Trial Different Several design choices strengthen the credibility of this trial: - **Scale:** 577 patients is an order of magnitude larger than prior curcumin chemoprevention studies. - **Duration:** A 2-year intervention with protocol-mandated colonoscopy at the end captures the real recurrence window. - **Formulation:** Theracurmin® is a submicron-powdered formulation specifically developed to improve bioavailability beyond standard turmeric powder. - **Endpoint sophistication:** The trial included both incidence-based and growth-based endpoints, revealing a signal that a simple yes/no recurrence measure would have missed. The authors note that the failure to reach significance on the primary endpoint may reflect the fact that curcumin's main mechanism is cytostatic—slowing cell proliferation—rather than cytotoxic. A growth-based endpoint is therefore more sensitive to its biological effect. ## Clinical Implications For patients with a history of colorectal adenomas, this trial adds a new layer of evidence to the curcumin discussion. It does not prove that curcumin prevents cancer, but it does demonstrate that a well-formulated, orally administered curcumin product can suppress the growth of recurrent precancerous lesions over a multi-year period. Important caveats remain: - The trial was conducted in a Japanese population; generalizability to other ethnicities requires confirmation. - The formulation used (Theracurmin®) is not identical to standard dietary turmeric or generic curcumin supplements. - Adenoma recurrence is an intermediate endpoint, not colorectal cancer incidence. - The effect was strongest in a subgroup (men, high baseline burden), not uniform across the whole cohort. Patients and clinicians should view this as a promising signal in a high-priority chemoprevention setting, not as a mandate for universal supplementation. ## Frequently Asked Questions Does this trial prove curcumin prevents colorectal cancer? No. The trial showed that curcumin suppressed the growth of recurrent adenomas, which are precancerous lesions. It did not measure colorectal cancer incidence directly. Prevention of cancer would require a much larger, longer study with cancer as the primary endpoint. Can I use regular turmeric powder instead of Theracurmin®? The trial used a proprietary submicron-powdered formulation (Theracurmin®) designed for enhanced bioavailability. Standard turmeric powder contains only about 3% curcumin by weight and has very poor oral absorption. The results should not be extrapolated directly to dietary turmeric or generic supplements. How long would I need to take curcumin to see a potential benefit? In this trial, participants took curcumin for 24 months and were assessed at the end of that period. Whether a shorter duration would produce similar effects is unknown. The suppressive effect on adenoma size was evident only after the full 2-year follow-up. Was curcumin safe over two years? Yes. Treatment-related adverse events were infrequent and mild in both groups. The safety profile was consistent with prior short-term studies of curcumin. In Plain Terms This was a large, well-designed trial in Japan that tested whether curcumin pills could stop precancerous colon polyps from growing back after removal. The pills did not stop polyps from returning entirely, but they did stop the returning polyps from getting big. Big polyps are the dangerous ones. The effect was strongest in men and in people who had many polyps to start with. Side effects were minimal. This is the strongest human evidence so far that curcumin may have a real role in slowing colon polyp growth, though it is not yet proven to prevent colon cancer outright. --- ## Shop Sanare Lab Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use. **Curcumin Turmeric 360 mg** High-purity curcumin extract (120 capsules) for daily supplementation. [ Buy Curcumin → ](https://sanarelab.com/products/curcumin-turmeric-360-mg-120-capsules?ref=sanarelab.science) **Disclaimer:** Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions. ## References 1. Takayama T, Okamoto K, Ishikawa H, et al. Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. *Am J Gastroenterol*. 2026 Aug 28\. doi:10.14309/ajg.0000000000004193\. PMID: 42669465. 2. Shan Y, et al. Theracurmin®: a submicron-powdered formulation of curcumin with enhanced bioavailability. *Nutr Cancer*. 2020;72(1):1-8. ## Medical Disclaimer This article is for informational purposes only and does not constitute medical advice. The research described is published in peer-reviewed journals but may not reflect the standard of care in your jurisdiction. Always consult a licensed healthcare professional before starting, stopping, or modifying any treatment or supplement regimen. Sanare Lab does not provide medical advice, diagnosis, or treatment.